Welcome to our dedicated page for Optinose news (Ticker: OPTN), a resource for investors and traders seeking the latest updates and insights on Optinose stock.
Optinose, Inc. (NASDAQ: OPTN) is a specialty pharmaceutical company focused on patients treated by ear, nose and throat (ENT) and allergy specialists. News related to Optinose often centers on its commercial product XHANCE, financial performance, clinical data, and corporate developments. The company reports net product revenue from sales of XHANCE and provides regular updates on prescription trends, including new prescriptions and total prescriptions, as well as commentary on inflection points in demand.
Investors and observers following OPTN news can expect recurring announcements of quarterly and full-year financial results, including net revenue from XHANCE, operating expenses, income or loss from operations, and balance sheet data such as cash and cash equivalents. Optinose also issues guidance on expected net revenue, average net revenue per prescription, and operating expenses, and may update this guidance based on evolving business conditions.
Beyond financial updates, Optinose news includes clinical and scientific developments. The company has highlighted peer-reviewed publications describing the efficacy of XHANCE, including randomized controlled trials in chronic rhinosinusitis patients with or without prior sinus surgery. These communications discuss outcomes such as symptom improvement, sinus opacification, and quality of life.
Corporate and capital markets news for OPTN includes announcements such as a 1-for-15 reverse stock split intended to help regain compliance with Nasdaq’s minimum bid price requirement, as well as leadership changes and appointments. Optinose has also announced that it has entered into a definitive agreement to be acquired by Paratek Pharmaceuticals, subject to shareholder and customary closing conditions. For those tracking OPTN, the news flow provides insight into the company’s commercial trajectory, financial condition, clinical positioning of XHANCE, and potential future corporate structure.
Optinose (NASDAQ:OPTN) announced that CEO Peter Miller will deliver a company overview and business update at the 2020 RBC Capital Markets Global Healthcare Virtual Conference on May 19, 2020, at 10:20 a.m. ET. Investors can access a live webcast of the presentation via the Investors page on the Optinose website. A replay will be available for 30 days post-event. Optinose focuses on patients treated by ENT and allergy specialists.
Optinose (NASDAQ:OPTN) reported first quarter 2020 financial results, highlighting a net revenue of $7.1 million from XHANCE, a 149% increase in prescriptions compared to Q1 2019. The COVID-19 pandemic impacted growth but prescriptions rose by 8% in late April. The company withdrew its 2020 revenue guidance due to uncertainty caused by the pandemic but plans to reduce operating expenses by $17 million. As of March 31, 2020, cash and cash equivalents were $148.5 million, with a net loss of $28.9 million, or $0.63 per share.
Summary not available.